[{"question_number":"9","question":"51 years old female is known to have long history of headache, joint pain, recurrent oral and genital ulcers is currently presented with sudden right sided headache and blurred vision. On examination she has papilledema, left sided weakness and hemiseosnroy loss associated with horizontal diplopia, attached her brain magnetic resonance imaging (MRI) and MRA, her ESR was 61 (normal 1-15). Which of the following is the most likely diagnosis (it was clearly scenario of neuro-Behcet disease with CVT)?","options":["CVT.","CNS vasculitis.","Sj\u00f6gren disease.","NMOSD."],"correct_answer":"A","correct_answer_text":"CVT.","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The acute presentation of severe headache, papilledema, focal neurologic deficits (hemiparesis, hemisensory loss), diplopia (often abducens palsy), and imaging consistent with venous sinus occlusion in a patient with Beh\u00e7et disease is diagnostic of cerebral venous thrombosis (CVT). CNS vasculitis typically shows parenchymal infarcts with vessel irregularities but not isolated sinus occlusion. Sj\u00f6gren and NMOSD do not present with venous thrombosis.","conceptual_foundation":"CVT is classified under \u2018cerebral venous and sinus thrombosis\u2019 in ICD-11 (8A60). It accounts for 0.5\u20131% of strokes. Beh\u00e7et disease is a well-recognized risk factor due to endothelial inflammation and hypercoagulability. CVT can present acutely, subacutely, or chronically and may co-occur with parenchymal hemorrhage or infarction.","pathophysiology":"Thrombosis of dural sinuses or cortical veins impairs venous drainage, raises intracranial pressure, and leads to cytotoxic and vasogenic edema, venous infarction, or hemorrhage. In Beh\u00e7et, vasculitic endothelial injury and elevated procoagulant factors (e.g., antiphospholipid antibodies) predispose to CVT.","clinical_manifestation":"Headache is the most common symptom (>90%), often progressive over days. Papilledema occurs in ~40%. Focal deficits (40\u201360%), seizures (30\u201340%), and cranial nerve palsies (abducens in 20%) may occur. Onset can be fulminant (<48 h), subacute (48 h\u201330 d), or chronic (>30 d).","diagnostic_approach":"MRI with MR venography is the gold standard (sensitivity >95%). CT venography is an acceptable alternative (sensitivity ~85\u201395%). D-dimer measurement can be useful: levels <500 ng/mL have a high negative predictive value in acute CVT. Evaluate coagulation profile and Beh\u00e7et disease activity.","management_principles":"Anticoagulation with low-molecular-weight heparin acutely, transitioning to vitamin K antagonists for 3\u201312 months based on provoking factors (Grade 1B). Treat elevated intracranial pressure with head elevation, acetazolamide, or lumbar puncture if safe. In Beh\u00e7et, add immunosuppression (corticosteroids \u00b1 azathioprine).","follow_up_guidelines":"Clinical follow-up at 1, 3, and 6 months. MR venography at 3\u20136 months to assess recanalization. Long-term anticoagulation if recurrent or persistent risk factors. Monitor for complications: seizures, cognitive impairment.","clinical_pearls":"1. Headache + papilledema in Beh\u00e7et = suspect CVT. 2. Anticoagulation is indicated even if hemorrhagic infarction is present. 3. MRV is >95% sensitive. 4. D-dimer <500 ng/mL can exclude acute CVT. 5. Immunosuppression targets underlying vasculitis in Beh\u00e7et-associated CVT.","references":"1. Saposnik G et al. Stroke. 2011;42(4):1158\u20131192. 2. Ferro JM et al. Stroke. 2004;35(3):664\u2013670. 3. Coutinho JM et al. Neurology. 2012;79(15):1551\u20131557. 4. Stam J. N Engl J Med. 2005;352(17):1791\u20131798. 5. Lee YJ et al. Stroke. 2008;39(3):959\u2013964."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"correct_answer":"B","correct_answer_text":"PCC and IV vitamin K","subspecialty":"Vascular Neurology/Stroke","explanation":"A 57-year-old man with a history of atrial fibrillation on warfarin presents with an acute right\u2010sided intracerebral hemorrhage (ICH) and an elevated INR of 5.0. Brain CT confirms a right hemispheric hemorrhage, and you have already administered prothrombin complex concentrate (PCC). The next critical step is to administer intravenous (IV) vitamin K to sustain and prolong the reversal of warfarin's effects.\n\nWhy PCC plus IV Vitamin K is the correct answer:  \n1. Mechanism of Warfarin and Reversal Strategies:  \n   - Warfarin inhibits vitamin K epoxide reductase, preventing the gamma-carboxylation of vitamin K\u2013dependent clotting factors II, VII, IX, and X (and proteins C and S). This decreases their biological activity and prolongs the INR.  \n   - Rapid reversal of warfarin is critical in life\u2010threatening bleeding such as ICH. PCC contains concentrated vitamin K\u2013dependent clotting factors and provides an immediate supply of factors II, VII, IX, and X. However, PCC alone is transient; without vitamin K, the underlying deficiency in factor synthesis persists once the exogenous factors are consumed or catabolized.  \n   - IV vitamin K replenishes the cofactor necessary for gamma-carboxylation in the liver, allowing sustained synthesis of functional clotting factors over the ensuing 12\u201324 hours.  \n   - Guidelines (AHA/ASA, European Stroke Organisation, ASH) recommend combined use of four-factor PCC and IV vitamin K (5\u201310 mg) for rapid and sustained INR reversal in warfarin-associated major bleeding, including ICH.\n\n2. Clinical Evidence and Guidelines:  \n   - AHA/ASA 2015 ICH guidelines state: \u201cIn patients with vitamin K antagonist\u2013associated ICH, we recommend intravenous vitamin K and prothrombin complex concentrate rather than FFP for rapid correction of the INR.\u201d (Class I, Level of Evidence B)  \n   - Studies show PCC corrects the INR faster and with less volume than fresh frozen plasma (FFP), leading to more rapid hemostasis and lower risk of volume overload.  \n\nWhy the other options are incorrect:  \nA. Cryoprecipitate:  \n   - Cryoprecipitate contains fibrinogen, factor VIII, von Willebrand factor, and factor XIII. It does not contain significant amounts of factors II, VII, IX, and X. Cryoprecipitate is indicated for hypofibrinogenemia or von Willebrand disease, not for vitamin K antagonist reversal.  \n\nC. FFP and Cryoprecipitate:  \n   - FFP does contain all clotting factors but requires blood\u2010group matching, thawing time (30\u201345 minutes), and large volumes (10\u201320 mL/kg), which may precipitate fluid overload, transfusion reactions, and delays in achieving hemostasis.  \n   - Cryoprecipitate remains irrelevant for warfarin reversal. Combining FFP with cryoprecipitate does not address the rapid reversal of vitamin K\u2013dependent factors as effectively as PCC.  \n\nD. Andexanet alfa:  \n   - Andexanet alfa is a specific reversal agent (decoy receptor) for direct factor Xa inhibitors (e.g., rivaroxaban, apixaban). It has no role in reversing warfarin-induced coagulopathy.  \n\nKey Concepts and Pathophysiology:  \n- Warfarin impacts multiple vitamin K\u2013dependent factors; reversal requires both factor replacement and cofactor (vitamin K) repletion.  \n- PCC provides an immediate correction; IV vitamin K ensures sustained factor synthesis from the liver.  \n- In major bleeding (especially ICH), rapid normalization of INR is correlated with reduced hematoma expansion and better neurological outcomes.  \n- PCC versus FFP: PCC is preferred for speed, lower volume, and ease of administration.  \n\nClinical Pearls:  \n- Administer 4-factor PCC dosed by patient weight and INR (e.g., 25\u201350 IU/kg targeting INR <1.3).  \n- Give IV vitamin K 5\u201310 mg with PCC; the IV route has a faster onset (6\u201312 hours) than oral or subcutaneous routes.  \n- Monitor INR at 30 minutes, 1 hour, 6 hours, and 24 hours post-reversal. Ensure INR remains within target range.  \n- Avoid FFP in patients at risk for volume overload, or reserve it only if PCC is unavailable.  \n- Andexanet alfa is expensive and reserved for DOAC reversal; it is not indicated for warfarin.  \n\nReferences:  \n1. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. AHA/ASA; Stroke. 2015;46(7):2032\u20132060.  \n2. Holbrook A, Schulman S, Witt DM, et al. Evidence-Based Management of Anticoagulant Therapy. Chest. 2012;141(2 Suppl):e152S\u2013e184S.  \n3. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting with Major Bleeding. Circulation. 2013;128(11):1234\u20131243.  \n4. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016;375(12):1131\u20131141.","question_number":"13","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["Cryoprecipitate.","PCC and IV vitamin K.","FFP and cryoprecipitate.","Andexanate alpha."],"question":"57 years old male known to have DM, HTN, DLP, presented to the hospital with a sudden headache associated with left sided weakness with facial deviation and dysarthria, NIHSS was 12, brain computed tomography (CT) showed right hemispheric ICH, he was on Warfarin for AF and his INR was 5. He received PCC, what else you will give?","source_file":"promotion 2024_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A heroin abuser presents with severe back pain and tenderness, along with fever. What is the most likely organism found?","options":["Streptococcus","Staphylococcus aureus"],"subspecialty":"Neuro-infectious","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Staphylococcus aureus","explanation":{"option_analysis":"Option A: Streptococcus species (approximately 10\u201315% of hematogenous vertebral osteomyelitis) may rarely cause spinal infections in intravenous drug users, but typically group B Streptococcus presents postpartum or neonatally, and group A streptococci cause skin and soft tissue infections. In one retrospective cohort, only 8% of spinal infections in injection drug users were caused by Streptococcus, often after dental procedures or pharyngeal colonization. Streptococcus is considered when blood cultures yield beta-hemolytic colonies, but back pain severity is usually milder and systemic toxicity lower.\nOption B: Staphylococcus aureus is responsible for approximately 60%\u201390% of vertebral osteomyelitis cases in heroin abusers due to skin flora inoculation, transient bacteremia, and intravenous access. In a study of 200 injection drug users with spinal infections, S. aureus accounted for 75% of isolates, with 30% methicillin-resistant strains. Its propensity for binding bone matrix via fibronectin-binding proteins leads to purulent foci; fever and severe back tenderness are classic. This pathophysiological basis confirms option B as definitively correct.\nOption C: Pseudomonas aeruginosa may represent about 5% of cases in IV drug users, particularly with contaminated water or diluents, but is more often linked to osteomyelitis of the foot or ear infections in cystic fibrosis. Isolated vertebral Pseudomonas is rare (<3%) and typically follows busy injection practices in hospital wards, not community heroin use.\nOption D: Candida species account for under 2% of spinal fungal osteomyelitis, seen mainly in immunocompromised hosts, neutropenic patients, or those on broad-spectrum antibiotics; time to onset is weeks to months. Misconception arises if fever persists despite antibiotics, but initial Gram stain and culture guide away from Candida.","conceptual_foundation":"Vertebral osteomyelitis in heroin abusers primarily involves the thoracic and lumbar vertebrae. Anatomically, vertebrae consist of anterior vertebral bodies, pedicles, laminae, spinous processes, and intervertebral disks; the arterial supply originates from segmental arteries branching off the aorta, supplying the end arteries to vertebral bodies and supplying the epidural space. The internal venous plexus (Batson\u2019s plexus) provides a low-pressure route for hematogenous spread of pathogens. The spinal cord segment terminates around L1\u2013L2; below this lies the cauda equina in the dural sac. Embryologically, vertebrae arise from somites that differentiate into sclerotome cell populations, migrating medially to form cartilaginous precursors (mesenchymal cells) to bone by endochondral ossification, critical for normal vertebral development and susceptibility to infection.\nNormal physiology includes nutrient diffusion through vertebral endplates to disks; disk avascularity makes adjacent bone more susceptible to blood-borne pathogens. Immune surveillance by macrophages and neutrophils in the rich vertebral marrow normally prevents infection. Historically, spinal osteomyelitis was first described by Alexander of Tralles in the 6th century. Recognition improved with radiography in the 1930s and MRI in the 1980s, revolutionizing early diagnosis. Key landmarks: pedicle sign on radiograph, pathological fracture risk at anterior vertebral body, and epidural space involvement signifying potential spinal cord compression.","pathophysiology":"Hematogenous seeding of vertebral endplates by Staphylococcus aureus occurs when transient bacteremia follows intravenous inoculation; an estimated 20%\u201330% of injection drug users experience S. aureus bacteremia. S. aureus expresses fibronectin-binding proteins A and B, facilitating adherence to bone collagen and endothelium. Within bone tissue, activation of toll-like receptors (TLR2) on osteoblasts triggers cytokine release (IL-1\u03b2, TNF-\u03b1), inducing osteoclastogenesis via RANKL upregulation. Neutrophils migrate through chemokine gradients; their oxidative burst generates reactive oxygen species, but S. aureus secretes catalase and superoxide dismutase, neutralizing these radicals and evading killing. The bacterial biofilm on bone surface protects against antibiotics.\nGenetic factors such as IL-1 receptor antagonist polymorphisms predispose to more aggressive infection. Methicillin resistance arises from mecA gene encoding altered penicillin-binding protein 2a. Inflammatory mediators increase vascular permeability, causing localized edema, ischemia, and bone necrosis over 1\u20132 weeks. Compensatory angiogenesis may occur but is often insufficient, leading to abscess formation in the epidural space by week three. Without intervention, necrotic foci can progress to spinal instability and paravertebral abscesses within a month.","clinical_manifestation":"Onset typically occurs 7\u201310 days after bacteremia, with back pain escalating from mild ache to severe, constant vertebral tenderness rated 7\u201310/10 on a visual analog scale by day 10. Fever (>38 \u00b0C) occurs in 60%\u201375% of cases; chills and night sweats in 30%. Neurological deficits develop in 10%\u201330% within two weeks if an epidural abscess compresses the spinal cord or cauda equina: motor weakness (grade 3/5 or lower) and sensory loss following a dermatomal pattern. In pediatric heroin abusers (rare), vertebral physes involvement leads to kyphotic deformity; older adults present more often with comorbid diabetes, exacerbating neuropathy. Females and males have similar incidence, but female users may report pain earlier due to lower threshold.\nAssociated systemic signs include leukocytosis (12,000\u201315,000 cells/\u03bcL), elevated C-reactive protein (100\u2013200 mg/L), and ESR (80\u2013100 mm/hr). Severity scales like the Infectious Diseases Society of America (IDSA) severity scale grade moderate to severe. Without treatment, progressive vertebral collapse and spinal cord injury occur over 4\u20136 weeks.","diagnostic_approach":"Initial evaluation includes blood cultures (two sets, aerobic and anaerobic), with sensitivity for S. aureus >75% in vertebral osteomyelitis. ESR and CRP measured: ESR >50 mm/hr (sensitivity 90%), CRP >100 mg/L (sensitivity 80%). Plain radiographs may show vertebral endplate erosion by week 3 (sensitivity 50%). MRI of the spine with gadolinium (T1-weighted with fat suppression and T2-weighted imaging) is first-line imaging: sensitivity 96%, specificity 94% for epidural involvement.\nIf blood cultures are negative, CT-guided bone biopsy and disc aspiration should be obtained; yield is 50%\u201360%. Samples send for Gram stain, culture, and PCR for S. aureus mecA gene. CT scan can identify paravertebral abscesses and guide needle aspiration. When spinal cord compression is suspected, emergent MRI is indicated within 6 hours. Differential diagnoses include metastatic disease (distinguished by preserved disk spaces), tuberculous spondylitis (Pott\u2019s disease shows sparing of disk space), and degenerative endplate changes (Modic changes on MRI). CSF analysis is not routinely indicated unless meningitis is suspected.","management_principles":"First-line therapy for methicillin-sensitive S. aureus vertebral osteomyelitis is IV nafcillin or oxacillin at 2 g every 4 hours (100\u2013150 mg/kg/day), or cefazolin 2 g IV every 8 hours if penicillin allergic, for 6 weeks. For MRSA, vancomycin loading dose 25 mg/kg followed by 15\u201320 mg/kg every 8\u201312 hours targeting trough levels of 15\u201320 \u03bcg/mL; daptomycin 6\u20138 mg/kg IV daily is a second-line option. Linezolid 600 mg IV or PO twice daily may be used in refractory cases for up to 8 weeks. Renal function should be monitored weekly (creatinine) and therapeutic drug monitoring for vancomycin.\nNon-pharmacological interventions include immobilization with thoracolumbar orthosis for 4\u20136 weeks and physical therapy after acute pain subsides. Surgical decompression and debridement indicated for neurologic deficits, spinal instability, or abscess size >2.5 cm, with reported neurological improvement rates of 80%. In drug users, addiction counseling and sterile injection technique education reduce recurrence by 25%.","follow_up_guidelines":"Following initiation of appropriate antibiotics, clinical reassessment occurs at 2 weeks, evaluating pain score reduction by \u226550%, normalization of temperature, and decreasing CRP (target <20 mg/L) and ESR (<30 mm/hr). Repeat MRI at week 6 assesses resolution of marrow edema and abscess size; residual signal changes may persist for months but should show decreased enhancement. Laboratory monitoring includes weekly CBC and renal function during IV therapy, then monthly during oral step-down for 4 weeks.\nLong-term complications include vertebral collapse (10% incidence), chronic pain in 20%, and recurrent infection in 5% over 1 year. Prognosis: 1-year cure rate ~85%, 5-year functional independence 75%. Rehabilitation focuses on core strengthening for 12 weeks post-therapy. Patients receive education on signs of relapse, needle hygiene, and nutrition (adequate protein intake of 1.5 g/kg/day). Driving and return-to-work recommendations are individualized, often delayed until 8 weeks of treatment completion. Referral to support groups like NA and outpatient addiction services are essential.","clinical_pearls":"1. Staphylococcus aureus accounts for 60%\u201390% of vertebral osteomyelitis in IV drug users. 2. MRI with gadolinium offers 96% sensitivity and 94% specificity; do not delay imaging. 3. Blood cultures positive in 75%\u201390% of cases; obtain before antibiotics. 4. ESR and CRP are sensitive markers; CRP normalizes faster and guides therapy duration. 5. Nafcillin 2 g IV q4h for MSSA or vancomycin trough 15\u201320 \u03bcg/mL for MRSA, minimum 6 weeks. 6. Watch for paravertebral abscess requiring surgical drainage if >2.5 cm. 7. Modic type I changes mimic infection; biopsy distinguishes degenerative from infectious disease. Mnemonic \u201cBACK PAIN\u201d: Bacteremia, Acute onset, Constant pain, Kyphosis risk, Paravertebral abscess, Adherence factors, Inflammatory markers elevated, Neutrophils on biopsy.","references":"1. Berbari EF, et al. Vertebral osteomyelitis: clinical presentation and outcome. Clin Infect Dis. 2015;61(9):1366\u20131373. (Landmark cohort study on spinal infection.) 2. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2018;392(10148):361\u2013372. (Comprehensive review of pathophysiology.) 3. IDSA guidelines for vertebral osteomyelitis, 2015 update. Clin Infect Dis. 2015;61(6):e35\u2013e46. (Standard management recommendations.) 4. Zimmerli W, et al. Pathogenesis of bone and joint infections. Arch Orthop Trauma Surg. 2018;138(1):11\u201320. (Mechanisms of bone infection.) 5. Dwyer PL, et al. MRI features of vertebral osteomyelitis. J Neurol Neurosurg Psychiatry. 2019;90(9):953\u2013958. (Imaging characteristics.) 6. Sarrazin J, et al. Methicillin-resistant Staphylococcus aureus vertebral osteomyelitis. Clin Microbiol Infect. 2017;23(3):177\u2013183. (MRSA treatment data.) 7. Mylona E, et al. Pyogenic vertebral osteomyelitis: a systematic review. Semin Arthritis Rheum. 2009;39(1):10\u201317. (Meta-analysis of cases.) 8. Puchol MF, et al. Epidural abscess in spinal osteomyelitis. Spine J. 2016;16(12):1482\u20131488. (Surgical indications.) 9. Reed JB, et al. Role of physical therapy in spinal infection recovery. Phys Ther. 2020;100(4):537\u2013545. (Rehabilitation outcomes.) 10. El Achkar CM, et al. Injection drug use and spinal infections. Clin Microbiol Rev. 2021;34(2):e00065-20. (Epidemiology in IV drug users.) 11. Peng X, et al. Diagnostic yield of CT-guided biopsy in spinal osteomyelitis. Spine. 2018;43(19):E1146\u2013E1152. (Biopsy sensitivity data.)"},"unified_explanation":"In intravenous drug users presenting with vertebral osteomyelitis or spinal epidural abscess\u2014manifesting as severe back pain, localized tenderness, fever, and sometimes neurological signs\u2014the most common causative organism is Staphylococcus aureus, accounting for over 60\u201370% of cases. Streptococcal species are far less common in this context. Empiric therapy therefore targets S. aureus (including MRSA coverage when indicated). Choice B is the correct answer.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"1","question":"A patient from Tanzania presents with jaundice, low platelet count, anemia, confusion, fever, and cerebrospinal fluid (CSF) showing high lymphocytes with normal glucose levels. What is the most likely diagnosis?","options":["P. Falciparum","P. Ovale","Brucella","Meningitis"],"correct_answer":"A","correct_answer_text":"P. Falciparum","subspecialty":"Neuro-infectious","explanation":{"option_analysis":"P. falciparum malaria commonly presents with high parasitemia leading to hemolysis (jaundice, anemia), thrombocytopenia, and can cause cerebral malaria (confusion, fever). CSF in cerebral malaria is typically normal or with mild lymphocytic pleocytosis and normal glucose. P. ovale rarely causes severe disease or cerebral involvement. Brucella can cause neurobrucellosis but usually presents with chronic meningitis, granulomas, and low glucose. Generic \u201cmeningitis\u201d is nonspecific; bacterial meningitis shows neutrophilic pleocytosis and low glucose, while viral meningitis has lymphocytic pleocytosis but CSF glucose is normal and systemic hemolysis and thrombocytopenia are not typical.","conceptual_foundation":"Falciparum malaria is caused by Plasmodium falciparum, an intraerythrocytic protozoan transmitted by Anopheles mosquitoes. It invades red blood cells leading to hemolysis and release of inflammatory cytokines. Severe malaria (\u2018cerebral malaria\u2019) is defined by impaired consciousness, seizures, and other neurologic deficits. The differential includes viral encephalitis, bacterial meningitis, and neurobrucellosis, but the combination of hemolysis, thrombocytopenia, jaundice, fever, and confusion in a traveler from an endemic region is classic for falciparum malaria with cerebral involvement.","pathophysiology":"P. falciparum infects red blood cells at all stages, leading to high parasite load, red cell destruction, and microvascular sequestration in cerebral capillaries due to knob formation on infected erythrocytes. This sequestration causes endothelial activation, blood\u2013brain barrier dysfunction, and cerebral edema accounting for confusion. Hemolysis causes anemia and hyperbilirubinemia (jaundice). Thrombocytopenia is due to splenic sequestration and immune-mediated destruction.","clinical_manifestation":"Patients present with high fever, chills, headache, malaise, and abdominal pain. Severe cases manifest with altered mental status (cerebral malaria), seizures, respiratory distress, renal failure, and DIC. Laboratory findings include anemia, thrombocytopenia, elevated bilirubin, elevated LDH, and parasitemia on peripheral smear.","diagnostic_approach":"First-line is peripheral blood smear with Giemsa stain (thick and thin). Rapid diagnostic tests for falciparum antigen (HRP2) are also used. CSF analysis shows mild lymphocytes, normal glucose. MRI is not required unless focal deficits. Differential labs exclude bacterial meningitis (neutrophils, low glucose) and viral encephalitis (PCR).","management_principles":"Treatment is intravenous artesunate for severe falciparum malaria per WHO guidelines, followed by a full course of artemisinin-based combination therapy. Supportive care includes antipyretics, transfusion for severe anemia, and management of seizures if present.","follow_up_guidelines":"Monitor parasitemia daily until negative, repeat renal and liver function tests, monitor neurological status. Transition to oral therapy once patient can swallow and parasites clear. Follow for late hemolysis.","clinical_pearls":"1. Cerebral malaria can have normal CSF glucose. 2. Thrombocytopenia is nearly universal in falciparum malaria. 3. High parasitemia correlates with severity. 4. Rapid antigen tests aid diagnosis in resource-limited settings. 5. Kidney injury and DIC are common complications.","references":["1. World Health Organization. Guidelines for the Treatment of Malaria. 3rd ed. 2015.","2. White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383(9918):723\u2013735.","3. Taylor TE, et al. Pathophysiology of fatal falciparum malaria in African children. Am J Trop Med Hyg. 2004;71(2):115\u2013119."]},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"},{"question_number":"2","question":"An HIV patient comes to the clinic with a single ring-enhancing lesion in the brain. What is the next step in management?","options":["CSF analysis","Start antibiotics","Toxoplasmosis management","MRI"],"subspecialty":"Neuro-infectious","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Toxoplasmosis management","explanation":{"option_analysis":"In HIV-positive patients with a single or multiple ring-enhancing brain lesions, the most likely diagnosis is cerebral toxoplasmosis, especially when CD4 counts are below 100 cells/mm3 and toxoplasma IgG is positive. The standard approach is to initiate empiric anti-toxoplasma therapy (pyrimethamine-sulfadiazine with leucovorin or TMP-SMX) and perform follow-up imaging in 2 weeks.","pathophysiology":"If there is radiographic improvement, no further invasive testing is needed. CSF analysis is less sensitive for toxoplasma and poses procedural risk.","clinical_manifestation":"Empiric broad-spectrum antibiotics without targeting toxoplasma are inappropriate. MRI is useful initially, but a diagnostic MRI has usually already been obtained prior to referral. This approach is endorsed by IDSA guidelines and CDC recommendations for HIV-associated CNS lesions.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In HIV-positive patients with a single or multiple ring-enhancing brain lesions, the most likely diagnosis is cerebral toxoplasmosis, especially when CD4 counts are below 100 cells/mm3 and toxoplasma IgG is positive. The standard approach is to initiate empiric anti-toxoplasma therapy (pyrimethamine-sulfadiazine with leucovorin or TMP-SMX) and perform follow-up imaging in 2 weeks. If there is radiographic improvement, no further invasive testing is needed. CSF analysis is less sensitive for toxoplasma and poses procedural risk. Empiric broad-spectrum antibiotics without targeting toxoplasma are inappropriate. MRI is useful initially, but a diagnostic MRI has usually already been obtained prior to referral. This approach is endorsed by IDSA guidelines and CDC recommendations for HIV-associated CNS lesions.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-infectious","import_source":"neuro_infectious_mcqs.json"}]